Home › Bayer, DNDi sign first agreement to develop new oral treatment for onchocerciasis
 

Keywords :   


Bayer, DNDi sign first agreement to develop new oral treatment for onchocerciasis

2014-12-10 14:44:18| Chemicals - Topix.net

Bayer HealthCare and the Drugs for Neglected Diseases initiative have signed an agreement under which Bayer will provide the active ingredient emodepside to support DNDi in its effort to develop a new oral drug to treat river blindness . The world's second leading infectious cause of blindness, river blindness is a neglected tropical disease caused by a filarial worm.

Tags: sign agreement treatment develop

Category:Chemicals

Latest from this category

All news
26.11ROSS VersaMix Multi Shaft Mixers are for Complex Formulations
26.11PPG Completes Sale of Silicas Products Business to QEMETICA
26.11¦nie¿ka Among Leaders of Sustainable Development in Poland
26.11Solvay Unveils Climate and Water Projects in Brazil with HRH Princess Astrid of Belgium
25.11PPG Recognized in Newsweeks Americas Greenest Companies List
25.11Axalta Wins Another Distinguished R&D 100 Award for Innovation
25.11Dunn-Edwards CEO Karl Altergott to Retire, COO Monte Lewis is Successor
25.11Global Market Insights: Auto Refinish Coating Market $17.79 Billion by 2032
Chemicals »
27.11110
27.11RIIZE BIGM
27.11BOX+BOX+2
27.11! 138
27.11 24
27.11702
27.11HOWL
27.11 THE CELL 5
More »